A better understanding of the factors capable of reducing CXCL1 expression may prove beneficial in many neurological disorders, as higher levels of this chemokine can be detected in CSF from patients experiencing neuromyelitis optica and stroke [59,89]. This evidence concerns the gene CXCL1 and nervous system disorder.